

Amendments to the Claims:

Please cancel Claims 2 and 6, and amend Claims 1, 4-5 and 7 as set forth below.

1. (Currently amended) A compound comprising a ecdysteroid ligand that specifically reacts with a ~~first~~ an ecdysone receptor ~~not naturally present in mammals,~~ and a molecular cage covalently bound to the ecdysteroid ligand that prevents reaction of the ecdysteroid ligand with the ~~first~~ ecdysone receptor, wherein the ecdysteroid ligand is released from the cage and capable of reacting with the ~~first~~ ecdysone receptor upon exposure of the compound to light and wherein the molecular cage comprises a nitromethoxybenzyl moiety ~~ligand is a steroid.~~

2-3. (Canceled)


4. (Currently amended) The compound of claim 1, wherein the ligand is an inhibitor of the ~~first~~ receptor.

5. (Currently amended) The compound of claim 1 ~~[[2]]~~, wherein the ligand is selected from the group consisting of ecdysone, 20-hydroxyecdysone, ponasterone A, muristerone A, and inokosterone, ~~3,5-di-tert-butyl-4-hydroxy-N-isobutyl-benzamide and a dibenzoylhydrazine.~~

6. (Canceled)

7. (Currently amended) The compound of claim 1 ~~[[6]]~~, wherein the nitromethoxybenzyl moiety is 1-methyl-4,5-dimethoxy-2-nitrobenzene.

8. (Previously presented) The compound of claim 7, wherein the compound is



9-10. (Canceled)

11. (Original) The compound of claim 1, wherein the molecular cage is a two-photon cage.

12-143. (Canceled)

144. (Previously presented) The compound of claim 1, wherein the light comprises wavelengths at 300-400 nm.

145. (Previously presented) The compound of claim 1, wherein the light comprises wavelengths at 325-375 nm.

146-149. (Canceled)

150. (Previously presented) The compound of claim 7, wherein the compound is

